Kayne Anderson Rudnick Investment Management
SRPT icon

Kayne Anderson Rudnick Investment Management’s Sarepta Therapeutics SRPT Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-75
Closed -$6K – 679
2022
Q1 		$6K Buy
+75
New +$5.74K ﹤0.01% 559
2021
Q1 		– Sell
-6
Closed -$1K – 709
2020
Q4 		$1K Buy
+6
New +$889 ﹤0.01% 662

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's SRPT Position: Q2 2022 in Review

Kayne Anderson Rudnick Investment Management sold out of Sarepta Therapeutics (SRPT) in Q2 2022, closing a stake of 75 shares — an estimated $6K sold.

Kayne Anderson Rudnick Investment Management first reported a position in SRPT in Q4 2020 and held it in 2 quarters. The position peaked at $6K in Q1 2022. 332 funds tracked by Wall St. Rank hold SRPT as of Q2 2022.

  • Kayne Anderson Rudnick Investment Management reported no remaining Sarepta Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 75 Sarepta Therapeutics shares in Q2 2022, an estimated $6K.
  • Kayne Anderson Rudnick Investment Management first reported a position in Sarepta Therapeutics in Q4 2020 and held it in 2 quarters.
  • Kayne Anderson Rudnick Investment Management's Sarepta Therapeutics position peaked at $6K in Q1 2022.
  • 332 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2022.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.